Allergy Immunotherapy Market to Reach US$ 2.81 Billion by 2031, Driven by Rising Allergy Prevalence and Shift Toward Disease-Modifying Therapies

Market Summary -
The global Allergy Immunotherapy market was estimated to be worth US$ 1,785 million in 2024 and is projected to reach a readjusted size of US$ 2,805 million by 2031, expanding at a CAGR of 7.0% during the forecast period 2025-2031.

According to QY Research, the newly released report titled "Allergy Immunotherapy Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031" presents an in-depth, data-driven evaluation of the global allergy immunotherapy landscape. The report combines historical analysis with forward-looking forecasts to deliver actionable insights into market dynamics, competitive structure, technological progress, and regional demand trends. It serves as a strategic resource for pharmaceutical companies, healthcare providers, investors, and policymakers seeking to understand long-term growth opportunities and challenges in allergy immunotherapy.

Get Full PDF Sample Copy of the Report (Including Full TOC, Tables & Charts):
https://www.qyresearch.in/request-sample/medical-devices-consumables-allergy-immunotherapy-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Industry Overview -
Allergy immunotherapy (AIT), also known as desensitization or hypo-sensitization, is a disease-modifying treatment designed to address the underlying causes of allergic disorders rather than merely alleviating symptoms. The therapy works by gradually exposing patients to increasing amounts of specific allergens, training the immune system to develop tolerance over time.

AIT has demonstrated strong clinical efficacy in the treatment of environmental allergies, allergic rhinitis, insect venom allergies, and allergic asthma, with benefits that often persist for years after treatment completion. Key therapeutic outcomes include symptom reduction, decreased reliance on symptomatic medications, and improved quality of life. While evidence for food allergy treatment remains limited, allergy immunotherapy continues to gain traction as a long-term, preventive approach in respiratory and environmental allergy management.

Market Drivers and Growth Dynamics -
The global allergy immunotherapy market is primarily driven by the rapidly increasing prevalence of allergic diseases, which now affect hundreds of millions of people worldwide. Urbanization, environmental pollution, climate change, and lifestyle shifts have contributed to a steady rise in allergic rhinitis, asthma, and seasonal allergies.
Growing awareness among patients and physicians regarding the long-term benefits of immunotherapy, compared with short-term symptom control, is accelerating adoption. In parallel, technological and formulation advancements, including the development of sublingual immunotherapy (SLIT) tablets and drops, have improved patient convenience and safety, broadening the therapy's appeal beyond specialist clinics.

Regulatory support for standardized allergen extracts, along with increasing interest in personalized and precision medicine, is further strengthening market momentum. As healthcare systems focus more on preventive and disease-modifying treatments, allergy immunotherapy is gaining recognition as a cost-effective long-term solution.

Market Challenges and Barriers -
Despite strong growth prospects, the allergy immunotherapy market faces notable challenges. Long treatment durations, typically spanning three to five years, can negatively impact patient adherence and result in high dropout rates. High upfront therapy costs and limited reimbursement coverage in several regions continue to restrict access, particularly in emerging economies.

In addition, specialized infrastructure and trained medical professionals are required for subcutaneous immunotherapy (SCIT), limiting adoption in low-resource settings. Safety concerns, including the risk of systemic allergic reactions, also present barriers-especially among pediatric and elderly populations. These factors collectively moderate market penetration and emphasize the need for safer, more convenient treatment formats.

Competitive Landscape -
The global allergy immunotherapy market is characterized by a relatively concentrated competitive environment, with established pharmaceutical and specialty allergy companies playing leading roles. Key players include ALK-Abello, Stallergenes Greer, Merck, Allergy Therapeutics, HAL, Hollister Stier, Leti, and WOLW Pharma.

These companies compete through product innovation, geographic expansion, regulatory approvals, and investments in next-generation allergen formulations. The development of standardized, high-quality allergen extracts and patient-friendly delivery formats remains a central competitive strategy.

Market Segmentation -

By Type -
► Subcutaneous Immunotherapy
► Sublingual Immunotherapy

By Application -
► Allergic Rhinitis
► Allergic Asthma
► Others

The report provides detailed segment-level analysis, highlighting demand trends, adoption patterns, and growth potential across therapy types and clinical applications.

Regional Analysis -
✔ North America (U.S., Canada, Mexico)
✔ Europe (Germany, France, UK, Italy, etc.)
✔ Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
✔ South America (Brazil, etc.)
✔ Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Europe and North America remain mature and well-established markets due to strong clinical adoption and reimbursement frameworks, while Asia-Pacific is emerging as a high-growth region supported by rising allergy prevalence and expanding healthcare infrastructure.

Reasons to Procure this Report -
► Gain a comprehensive understanding of global allergy immunotherapy market dynamics through 2031
► Identify high-growth therapy formats and application segments
► Analyze competitive positioning and market share of leading companies
► Assess regional opportunities and regulatory influences
► Support strategic planning with reliable revenue and volume forecasts

Key Questions Answered in the Report -
► What will be the size and growth rate of the global allergy immunotherapy market by 2031?
► Which therapy types and indications will drive future demand?
► How is the competitive landscape evolving among key manufacturers?
► What barriers could limit wider adoption of allergy immunotherapy?
► Which regions offer the most attractive expansion opportunities?

Request for Pre-Order / Enquiry Link:
https://www.qyresearch.in/pre-order-inquiry/medical-devices-consumables-allergy-immunotherapy-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Content:

1 Market Overview
1.1 Allergy Immunotherapy Product Introduction
1.2 Global Allergy Immunotherapy Market Size Forecast
1.2.1 Global Allergy Immunotherapy Sales Value (2020-2031)
1.2.2 Global Allergy Immunotherapy Sales Volume (2020-2031)
1.2.3 Global Allergy Immunotherapy Sales Price (2020-2031)
1.3 Allergy Immunotherapy Market Trends & Drivers
1.3.1 Allergy Immunotherapy Industry Trends
1.3.2 Allergy Immunotherapy Market Drivers & Opportunity
1.3.3 Allergy Immunotherapy Market Challenges
1.3.4 Allergy Immunotherapy Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Allergy Immunotherapy Players Revenue Ranking (2024)
2.2 Global Allergy Immunotherapy Revenue by Company (2020-2025)
2.3 Global Allergy Immunotherapy Players Sales Volume Ranking (2024)
2.4 Global Allergy Immunotherapy Sales Volume by Company Players (2020-2025)
2.5 Global Allergy Immunotherapy Average Price by Company (2020-2025)
2.6 Key Manufacturers Allergy Immunotherapy Manufacturing Base and Headquarters
2.7 Key Manufacturers Allergy Immunotherapy Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Allergy Immunotherapy
2.9 Allergy Immunotherapy Market Competitive Analysis
2.9.1 Allergy Immunotherapy Market Concentration Rate (2020-2025)
2.9.2 Global 5 and 10 Largest Manufacturers by Allergy Immunotherapy Revenue in 2024
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Allergy Immunotherapy as of 2024)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Subcutaneous Immunotherapy
3.1.2 Sublingual Immunotherapy
3.2 Global Allergy Immunotherapy Sales Value by Type
3.2.1 Global Allergy Immunotherapy Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Allergy Immunotherapy Sales Value, by Type (2020-2031)
3.2.3 Global Allergy Immunotherapy Sales Value, by Type (%) (2020-2031)
3.3 Global Allergy Immunotherapy Sales Volume by Type
3.3.1 Global Allergy Immunotherapy Sales Volume by Type (2020 VS 2024 VS 2031)
3.3.2 Global Allergy Immunotherapy Sales Volume, by Type (2020-2031)
3.3.3 Global Allergy Immunotherapy Sales Volume, by Type (%) (2020-2031)
3.4 Global Allergy Immunotherapy Average Price by Type (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Allergic Rhinitis
4.1.2 Allergic Asthma
4.1.3 Others
4.2 Global Allergy Immunotherapy Sales Value by Application
4.2.1 Global Allergy Immunotherapy Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Allergy Immunotherapy Sales Value, by Application (2020-2031)
4.2.3 Global Allergy Immunotherapy Sales Value, by Application (%) (2020-2031)
4.3 Global Allergy Immunotherapy Sales Volume by Application
4.3.1 Global Allergy Immunotherapy Sales Volume by Application (2020 VS 2024 VS 2031)
4.3.2 Global Allergy Immunotherapy Sales Volume, by Application (2020-2031)
4.3.3 Global Allergy Immunotherapy Sales Volume, by Application (%) (2020-2031)
4.4 Global Allergy Immunotherapy Average Price by Application (2020-2031)
5 Segmentation by Region
5.1 Global Allergy Immunotherapy Sales Value by Region
5.1.1 Global Allergy Immunotherapy Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Allergy Immunotherapy Sales Value by Region (2020-2025)
5.1.3 Global Allergy Immunotherapy Sales Value by Region (2026-2031)
5.1.4 Global Allergy Immunotherapy Sales Value by Region (%), (2020-2031)
5.2 Global Allergy Immunotherapy Sales Volume by Region
5.2.1 Global Allergy Immunotherapy Sales Volume by Region: 2020 VS 2024 VS 2031
5.2.2 Global Allergy Immunotherapy Sales Volume by Region (2020-2025)
5.2.3 Global Allergy Immunotherapy Sales Volume by Region (2026-2031)
5.2.4 Global Allergy Immunotherapy Sales Volume by Region (%), (2020-2031)
5.3 Global Allergy Immunotherapy Average Price by Region (2020-2031)
5.4 North America
5.4.1 North America Allergy Immunotherapy Sales Value, 2020-2031
5.4.2 North America Allergy Immunotherapy Sales Value by Country (%), 2024 VS 2031
5.5 Europe
5.5.1 Europe Allergy Immunotherapy Sales Value, 2020-2031
5.5.2 Europe Allergy Immunotherapy Sales Value by Country (%), 2024 VS 2031
5.6 Asia Pacific
5.6.1 Asia Pacific Allergy Immunotherapy Sales Value, 2020-2031
5.6.2 Asia Pacific Allergy Immunotherapy Sales Value by Region (%), 2024 VS 2031
5.7 South America
5.7.1 South America Allergy Immunotherapy Sales Value, 2020-2031
5.7.2 South America Allergy Immunotherapy Sales Value by Country (%), 2024 VS 2031
5.8 Middle East & Africa
5.8.1 Middle East & Africa Allergy Immunotherapy Sales Value, 2020-2031
5.8.2 Middle East & Africa Allergy Immunotherapy Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Allergy Immunotherapy Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Allergy Immunotherapy Sales Value and Sales Volume
6.2.1 Key Countries/Regions Allergy Immunotherapy Sales Value, 2020-2031
6.2.2 Key Countries/Regions Allergy Immunotherapy Sales Volume, 2020-2031
6.3 United States
6.3.1 United States Allergy Immunotherapy Sales Value, 2020-2031
6.3.2 United States Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Allergy Immunotherapy Sales Value, 2020-2031
6.4.2 Europe Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Allergy Immunotherapy Sales Value, 2020-2031
6.5.2 China Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
6.5.3 China Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Allergy Immunotherapy Sales Value, 2020-2031
6.6.2 Japan Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Allergy Immunotherapy Sales Value, 2020-2031
6.7.2 South Korea Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Allergy Immunotherapy Sales Value, 2020-2031
6.8.2 Southeast Asia Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Allergy Immunotherapy Sales Value, 2020-2031
6.9.2 India Allergy Immunotherapy Sales Value by Type (%), 2024 VS 2031
6.9.3 India Allergy Immunotherapy Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 ALK-Abello
7.1.1 ALK-Abello Company Information
7.1.2 ALK-Abello Introduction and Business Overview
7.1.3 ALK-Abello Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 ALK-Abello Allergy Immunotherapy Product Offerings
7.1.5 ALK-Abello Recent Development
7.2 Stallergenes Greer
7.2.1 Stallergenes Greer Company Information
7.2.2 Stallergenes Greer Introduction and Business Overview
7.2.3 Stallergenes Greer Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Stallergenes Greer Allergy Immunotherapy Product Offerings
7.2.5 Stallergenes Greer Recent Development
7.3 Merck
7.3.1 Merck Company Information
7.3.2 Merck Introduction and Business Overview
7.3.3 Merck Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 Merck Allergy Immunotherapy Product Offerings
7.3.5 Merck Recent Development
7.4 Allergy Therapeutics
7.4.1 Allergy Therapeutics Company Information
7.4.2 Allergy Therapeutics Introduction and Business Overview
7.4.3 Allergy Therapeutics Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Allergy Therapeutics Allergy Immunotherapy Product Offerings
7.4.5 Allergy Therapeutics Recent Development
7.5 HAL
7.5.1 HAL Company Information
7.5.2 HAL Introduction and Business Overview
7.5.3 HAL Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 HAL Allergy Immunotherapy Product Offerings
7.5.5 HAL Recent Development
7.6 Holister Stier
7.6.1 Holister Stier Company Information
7.6.2 Holister Stier Introduction and Business Overview
7.6.3 Holister Stier Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Holister Stier Allergy Immunotherapy Product Offerings
7.6.5 Holister Stier Recent Development
7.7 Leti
7.7.1 Leti Company Information
7.7.2 Leti Introduction and Business Overview
7.7.3 Leti Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Leti Allergy Immunotherapy Product Offerings
7.7.5 Leti Recent Development
7.8 WOLW Pharma
7.8.1 WOLW Pharma Company Information
7.8.2 WOLW Pharma Introduction and Business Overview
7.8.3 WOLW Pharma Allergy Immunotherapy Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 WOLW Pharma Allergy Immunotherapy Product Offerings
7.8.5 WOLW Pharma Recent Development
8 Industry Chain Analysis
8.1 Allergy Immunotherapy Industrial Chain
8.2 Allergy Immunotherapy Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Allergy Immunotherapy Sales Model
8.5.2 Sales Channel
8.5.3 Allergy Immunotherapy Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

QY Research PVT. LTD.
315 Work Avenue,
Raheja Woods,
6th Floor, Kalyani Nagar,
Yervada, Pune - 411060,
Maharashtra, India
India: (O) +91 866 998 6909
USA: (O) +1 626 295 2442
Email: hitesh@qyresearch.com
Web: www.qyresearch.in

About Us -
QY Research, founded in 2007, is a globally trusted market research and consulting firm serving clients across more than 80 countries. With over 50,000 satisfied clients worldwide, QY Research delivers high-quality syndicated and customized research across healthcare, pharmaceuticals, chemicals, electronics, and industrial markets. Through rigorous methodologies and deep domain expertise, QY Research empowers organizations to make data-driven decisions and achieve sustainable long-term growth.

This release was published on openPR.